Evaluating Safety, Effectiveness, and Resource Efficiency in Management Strategies for Intermediate Risk Choledocholithiasis: Defining the Optimal Approach

INTRODUCTION: Optimal management of emergency department patients with intermediate-risk choledocholithiasis (IR-CDL) remains undefined. At a safety-net hospital where timely patient throughput is essential, we hypothesized that forgoing additional preoperative diagnostics and proceeding directly to laparoscopic cholecystectomy (LC) ± intraoperative cholangiogram (IOC) is a safe, effective, and resource-efficient strategy. METHODS: Adults with IR-CDL who underwent cholecystectomy during index hospitalization from 2016 to 2020 were included. IR-CDL was defined as total bilirubin 1.8 to 4.0 mg/dL, common bile duct (CBD) >6 mm, or gallstone pancreatitis on admission. Safety was assessed using the rate of CBD injury, reoperation, readmission, and retained CBD stones within 30 days of discharge. Effectiveness was assessed using the rate of successful endoscopic CBD clearance. Efficiency was measured using hospital length of stay (LOS) and direct and total cost. Patients taken direct-to-operating room (OR) for LC ± IOC were compared with those who received preoperative magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic retrograde cholangiopancreatography (ERCP) (“additional-workup”). RESULTS: Of 655 patients, 611 (93%) were direct-to-OR and 44 (7%) were additional workup. Demographics were similar between groups. There was no difference in CBD injury, reoperation, readmission, or retained stones after discharge (all p > 0.05; Table). Of direct-to-OR patients who underwent LC+IOC, 34% had choledocholithiasis. Rates of successful endoscopic CBD clearance were similar between preoperative and postoperative ERCP (97% vs 100%, p = 0.96). Direct-to-OR patients had a shorter median hospital LOS by 38.5 hours and lower median direct and total cost by $5,121/patient and $8,535/patient, respectively.TableCONCLUSION: Proceeding directly to the OR for LC ± IOC expedites treatment of IR-CDL at lower cost without compromising safety or efficacy. These findings help clarify optimal management of IR-CDL.